Why Are Windtree Therapeutics Shares Trading Higher Today?

Loading...
Loading...

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 of 2022.

  • The 20-subject Phase 2 trial is designed to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in mechanically ventilated patients due to this COVID-19 associated acute lung injury. 
  • Functional changes in gas exchange and lung compliance are also being measured.
  • Lucinactant is a synthetic surfactant structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 (sinapultide). 
  • This 21-amino acid peptide is designed to imitate the human surfactant protein B (SP-B). S
  • Price Action: WINT shares are up 21.20% at $1.37 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...